Once Daily Trospium chloride (cas 10405-02-4) is Effective and Well Tolerated for the Treatment of Overactive Bladder: Results From a Multicenter Phase III Trial
-
Add time:08/03/2019 Source:sciencedirect.com
PurposeAn extended release formulation of Trospium chloride (cas 10405-02-4) was recently developed for the once daily treatment of overactive bladder. We investigated the safety, efficacy and tolerability of 60 mg trospium chloride once daily.
We also recommend Trading Suppliers and Manufacturers of Trospium chloride (cas 10405-02-4). Pls Click Website Link as below: cas 10405-02-4 suppliers
Prev:Extended-Release Trospium chloride (cas 10405-02-4) Improves Quality of Life in Overactive Bladder
Next:Factors of adherence to treatment with trospium in employees) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Effects of Tolterodine and Trospium chloride (cas 10405-02-4) on Renal Damage Induced by Partial Upper Urinary Tract Obstruction08/08/2019
- Effects of Combined Use of Trospium chloride (cas 10405-02-4) and Melatonin on In Vitro Contractility of Rat Urinary Bladder08/07/2019
- Lipid-based intravesical drug delivery systems with controlled release of Trospium chloride (cas 10405-02-4) for the urinary bladder08/06/2019
- Role of Trospium chloride (cas 10405-02-4) in Brachytherapy-Related Detrusor Overactivity08/05/2019
- Factors of adherence to treatment with trospium in employees08/04/2019
- Extended-Release Trospium chloride (cas 10405-02-4) Improves Quality of Life in Overactive Bladder08/02/2019
- Trospium chloride (cas 10405-02-4) for overactive bladder may induce central nervous system adverse events08/01/2019
- Increasing dissolution of Trospium chloride (cas 10405-02-4) by co-crystallization with urea07/31/2019
- Trospium chloride (cas 10405-02-4) is absorbed from two intestinal “absorption windows” with different permeability in healthy subjects07/30/2019